Unichem: Strong growth - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Unichem: Strong growth

Jun 20, 2002

A wider therapeutic reach, increasing presence in exports and restructuring benefits have helped Unichem Labs display robust numbers for FY02. The company's margins have shown steady improvement in the last two years due to product introductions in high growth segments. The company ended FY02 with a 55% growth in net profits.

(Rs m)FY01FY02% change
Sales2,190 2,689 22.7%
Other Income2725-7.0%
Expenditure1,854 2,233 20.5%
Operating Profit (EBDIT)33745635.3%
Operating Profit Margin (%)15.4%16.9%
Interest (net)5045-9.4%
Depreciation596610.3%
Profit before Tax25437045.4%
Tax2261.86185.1%
Extraordinary Item-340-
Profit after Tax/(Loss)19930855.0%
Net profit margin (%)9.1%11.5%
No. of Shares (eoy) (m)8.58.5
Diluted Earnings per share*23.436.2
P/E (at current price)6.8
*- annualised

The company has been launching products in the high margin segments in the last two years which has helped it enhance its overall profitability margins. The company introduced eight products last fiscal. The company has identified anti-diabetes as its core area of growth going forward. Some of the products introduced include Glitase a drug used to treat diabetes, TG-tor a cholesterol reducing drug, Roff-50 a painkiller, Erix Unichem's version of Pfizer's blockbuster drug Viagra and Nutreva a Protein supplement. It plans to introduce 10 products in the current year.

Last year the company launched two new divisions - Foreva (catering exclusively to women healthcare) and Molecular Generics, which cater to the generics market. The growth drivers were tranquilisers and anti-rheumatics, which registered growth of 18% and 73.4% respectively. While tranquilisers contribute 11.4% to the total turnover, anti-rheumatics contribute around 8.5%. Cardiovascular and CNS also registered healthy growth rates. The growth in the cardiovascular segment was driven by Corvadil-A (hypotensive combinations) and Loprin (anticoagulents). Serta (antidepressant), with a growth rate of 92.9%, was the key growth driver for the CNS category. Cardiovascular and CNS together contribute around 10% to the total turnover.

Unichem is foraying in the UK through a JV with the former directors of the Bioglan group in Ireland. The company will hold a 60% stake in the JV, christened Niche Generics, while the balance 40% will be held by the foreign management team. Niche Generics will buy certain assets of the Bioglan group including the manufacturing facility in Ireland, range of product licenses (market authorisations) representing a present business of approximately 4 m pounds spread across the regulated markets of the European Union and UK. Unichem has already invested 2 m pounds and will invest another 1 m pounds to fund Niche Generics' working capital requirements.

The stock currently trades at Rs 247 at a P/E of 7x FY02 earnings. The company is trading at a discount to its peers in the industry. No doubt that the company has ventured into some high growth areas, however, competition is stiff in these segments and the company will require considerable time and resources to establish its brands here.

Equitymaster requests your view! Post a comment on "Unichem: Strong growth". Click here!

  

More Views on News

5 Indian Pharma Companies Riding the Vaccination Wave (Views On News)

Sep 3, 2021

These companies are likely to benefit the most from Covid-19 vaccines.

Apollo Hospitals' Shares Rally Over 5%, Hit Record-High on Strong Results (Views On News)

Aug 16, 2021

The company reported a 73% YoY increase in revenue driven by an uptick in the hospital and pharmacy business.

J B Chemicals & Pharma's Decent Performance Puts Stock in Focus (Views On News)

Aug 13, 2021

The company seeks to expand the market for prescription lozenges with new launches this year.

Cipla Shares Tank Despite Strong Earnings (Views On News)

Aug 6, 2021

The stock fell 3.5% even as the company reported numbers higher than analysts' expectations.

Glenmark Life Sciences Makes Lacklustre Debut. Shares List At 4% Premium (Views On News)

Aug 6, 2021

Glenmark Life Sciences' IPO had received strong response from investors as the offer was subscribed 44.17 times.

More Views on News

Most Popular

Sansera Engineering IPO: Key Points to Consider (Views On News)

Sep 8, 2021

This IPO is a pure OFS and the company is looking to raise Rs 12.8 bn at the upper price band of Rs 744.

5 Stocks that Turned Rs 1 Lakh into Rs 1 Crore (Views On News)

Sep 7, 2021

Patience is one of the biggest virtues you need to have if you want to become a crorepati in the stock market.

The Top Stocks to Sell in this Bull Market (Profit Hunter)

Sep 8, 2021

When I saw the list of so-called 'value stocks' published by a leading brokerage, my worst fears came true.

5 Indian Companies that are Leading the AI Race (Views On News)

Sep 9, 2021

During the pandemic, India reported the highest increase in the use of AI at 45% compared to other major economies. AI has potential to add US$90 bn to the Indian economy by 2025.

How to Create a Second Income from Trading (Profit Hunter)

Sep 10, 2021

My trading system that works in all kinds of markets.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2021
Get our special report Multibagger Stocks Guide (2021 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

UNICHEM LAB SHARE PRICE


Sep 17, 2021 (Close)

TRACK UNICHEM LAB

  • Track your investment in UNICHEM LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

UNICHEM LAB 5-YR ANALYSIS

COMPARE UNICHEM LAB WITH

MARKET STATS